Stay updated with breaking news from Ongoing Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Acceleron Pharma Inc. (Nasdaq: XLRN), a publicly traded biopharmaceutical company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Acceleron for $180 per share ...
/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful...
/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful...
Chickasaw Journal E-Edition Delivery Are you a Chickasaw Journal subscriber? Sign up to view our weekly e-editions each Wednesday with just a click. Itawamba Times E-Edition Delivery Are you an Itawamba Times subscriber? Sign up to view our weekly e-editions each Wednesday with just a click. Monroe Journal E-Edition Delivery Are you a Monroe Journal subscriber? Sign up to view our weekly e-editions each Wednesday with just a click. New Albany Gazette E-Edition Delivery Are you a New Albany Gazette subscriber? Sign up to view our weekly e-editions each Wednesday with just a click. Ponto...
Message : Required fields NT219 was Well-tolerated with Minimal Adverse Events in Initial Clinical Data from Ongoing Phase 1/2 Clinical Trial in Adults with Advanced Solid Tumors Partial Response Observed in a Patient with Refractory Gastroesophageal Junction Cancer REHOVOT, Israel, June 4, 2021 - Purple Biotech Ltd. ('Purple Biotech', or the 'Company') (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, announced today the presentation of new data from the first dose level cohor...